|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-1-20
|
|
pubmed:abstractText |
A combination of docetaxel and fluorouracil (DF) was evaluated in an outpatient setting and compared with epirubicin, cisplatin, and fluorouracil (ECF), which served as an internal control arm to avoid selection bias.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
494-501
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15659494-Adenocarcinoma,
pubmed-meshheading:15659494-Adult,
pubmed-meshheading:15659494-Aged,
pubmed-meshheading:15659494-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15659494-Cisplatin,
pubmed-meshheading:15659494-Disease Progression,
pubmed-meshheading:15659494-Epirubicin,
pubmed-meshheading:15659494-Female,
pubmed-meshheading:15659494-Fluorouracil,
pubmed-meshheading:15659494-Humans,
pubmed-meshheading:15659494-Infusions, Intravenous,
pubmed-meshheading:15659494-Male,
pubmed-meshheading:15659494-Middle Aged,
pubmed-meshheading:15659494-Stomach Neoplasms,
pubmed-meshheading:15659494-Survival Analysis,
pubmed-meshheading:15659494-Taxoids,
pubmed-meshheading:15659494-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
|
|
pubmed:affiliation |
Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charité, Universitätsmedizin Berlin, Campus Virchow-Klinkum, Augustenburger Platz 1, 13353 Berlin, Germany. peter.thuss@charite.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
